Objectives: This research surveyed Tier 3 adult weight management services in England commissioned by integrated care boards (ICBs) across England in financial year 2022-2023.

About 20% of adolescents have obesity, a figure that is expected to rise over the next few decades. And while popular weight loss drugs are a potential tool for physicians caring for these young people, many doctors are not yet sure that these drugs are ready to be front-line treatments.

Hi. I'm Tamaan K. Osbourne-Roberts, family medicine physician and lifestyle medicine physician, here to discuss GLP-1 receptor agonist (RA) contraindications — the skinny on when not to prescribe.

Combined exposure to dioxins and dioxin-like polychlorinated biphenyls (DL-PCBs) is significantly associated with an increased risk for obesity in adults, with 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) showing the greatest contribution.

Aerobic exercise shows a linear relationship with weight loss, with 30 minutes of weekly exercise linked to reduced body weight, waist circumference, and body fat in adults who were overweight or had obesity.

Glucagon-like peptide 1 (GLP-1) medications have become a powerful weight loss tool in a country where 40% of the population is obese. Patients taking these medications can experience weight loss, a life changing amount for those who have been struggling with weight and related health problems for much of their lives.

LOS ANGELES — Newer glucose-lowering drugs reduce the risk for late-onset seizures and epilepsy by 24%, with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) cutting the risk by 33%, according to a new meta-analysis.